A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/179
A61K 31/00 (2006.01) A61K 31/445 (2006.01) A61K 31/475 (2006.01) A61K 31/495 (2006.01) A61K 31/54 (2006.01) A61K 31/55 (2006.01)
Patent
CA 1048932
ABSTRACT OF THE DISCLOSURE Known neuroleptic drugs used to treat schizophrenia include phenothiazines such as chloropromaxine; butyrophenones such as haloperiodal and others such as pimocide and clozapine. Underirable side effects of neuroleptic drugs include sedation and tardive dyskinesias. The latter side effect is particularly important because it results in involuntary muscle movements especially of the face and mouth which become reversible. The onset of this side effect is directly related to the amounts of and length of time which a neuroleptic drug is used in treatment. There has now been discovered a composition for treating schizophrenia and a method and composition for potentiating the beneficial effects and for reducing the side effects of neuroleptic drugs. The foregoing results are obtained by administering to a schizophrenic an effects amount of a gabergic compound or by coadministering to a schizophrenic a neuroleptic drug and a potentiating amount of a gabergic compound such as gammahydroxybutyrolac- tone, gammahydroxybutyrate, aminooxyacetic acid or a compound having the structural formula Image wherein R is halogen or trifluoromethyl and salts thereof. The present invention further relates to a composition comprising a neuroleptic drug and a potentiating amount of a gabergic compound together with a suitable pharmaceutical carrier.
227970
LandOfFree
Composition for treating schizophrenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for treating schizophrenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for treating schizophrenia will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1138962